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Reply to Aitken et al., “Should
Piperacillin-Tazobactam Be Used as
Deﬁnitive Therapy against
Enterobacteriaceae Harboring Inducible
AmpC -Lactamases?”
Lucy Cheng,a Brian C. Nelson,b Monica Mehta,b Qiuhu Shi,c
Angela Gomez-Simmonds,a Anne-Catrin Uhlemanna
Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New
York, USAa; NewYork-Presbyterian Hospital, New York, New York, USAb; New York Medical College, Valhalla,
New York, USAc
We appreciate Aitken et al.’s careful review (1) of our recent paper assessing the useof piperacillin-tazobactam for the treatment of bloodstream infections caused by
Enterobacteriaceae harboring AmpC -lactamases (2). We respectfully disagree with
their assertion that the numerical increase in mortality seen with the use of piperacillin-
tazobactam compared to the mortalities of patients on carbapenems and/or cefepime
in our and other studies suggests that inferior outcomes are to be expected with
piperacillin-tazobactam.
Aitken et al. are correct to point out that the odds ratio (OR) for the 30-day survival,
not mortality, of patients receiving piperacillin-tazobactam versus that of patients
receiving cefepime or meropenem was 0.5 in the propensity-matched data set. There-
fore, the OR for 30-day mortality was 2.0 (95% conﬁdence interval, 0.5 to 7.7), repre-
senting 3 additional deaths in the piperacillin-tazobactam group. This result was not
statistically signiﬁcant (P  0.33), indicating that we were unable to detect an associ-
ation between the treatment regimen and the occurrence of mortality in this study. It
is worth noting that the large conﬁdence intervals reported here suggest a low level of
the precision of the OR. Thus, it is inappropriate to draw a ﬁrm conclusion about the
relative odds of mortality based on its numerical value alone. As we pointed out in our
publication, propensity score matching lowered our ability to detect differences in
outcomes. In the overall cohort, the OR for 30-day survival was 1.16, as reported, and
the OR for 30-day mortality was 0.86 (95% conﬁdence interval, 0.3 to 2.3; P  0.8). It is
worth noting that in creating the propensity score-matched cohort, fewer deaths were
excluded from the piperacillin-tazobactam group (3/9) than from the carbapenem/
cefepime group (6/9).
Aitken et al. also suggested that using multivariable logistic regression is preferred
to propensity score matching for some data sets. We opted for propensity score
matching to minimize differences between baseline characteristics of treatment groups. In
addition, a low number of outcome events in our data set made it difﬁcult to perform
multivariate models. Multivariable analyses of the overall cohort were attempted by
incorporating variables that were signiﬁcantly different between treatment groups, but
these models demonstrated poor ﬁt. However, they also showed no association be-
tween treatment groups and mortality, supporting our ﬁndings from the propensity
score-matched analysis.
The commenters further mention a paper by Harris and colleagues from 2017 with
similar results (i.e., a numerically higher rate of recurrence of Enterobacter spp. bacte-
remia without a statistically signiﬁcant difference) and a small patient population (3).
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We direct them to a much larger meta-analysis also conducted by Harris et al. in 2016
that included 11 studies and revealed no strong evidence to suggest the superiority of
carbapenems to other treatment regimens, including -lactamase/-lactamase inhibi-
tors, in patients with bloodstream infections due to Enterobacteriaceae with AmpC
-lactamases (4). We welcome future studies of the efﬁcacy of non-carbapenem-
containing regimens, such as piperacillin-tazobactam, for the treatment of AmpC-
harboring Enterobacteriaceae. As we discussed in our original paper, prospective studies
and meta-analyses are needed to further delineate patient populations that might
beneﬁt from this treatment approach and to identify speciﬁc risk factors warranting the
use of carbapenem or cefepime.
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